Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance therapy with obefazimod in ulcerative colitis
jRCT2031230257Phase 3Active, not recruiting
- Sponsor
- Abivax
- Start
- Aug 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Obefazimod maintenance arm with Placebo maintenance arm (2 arms). Primary endpoints: Clinical remission at Week 44 (Part 1) and Safety and tolerability of obefazimod at Week 44 (Part 2). Started Aug 2023; status: active, not recruiting.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031230257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230257.